What is it about?
We tested the expression of biomarkers in the blood in patients treated with the topical anti-psoriatic therapy Enstilar. This is a combination of calcipotriol and betamethasone dipropionate in a foam formulation that reduce the psoriasis score significantly. We selected 50 severe patients from a 12 week study with this product and tested their serum for the level of various biomarkers at baseline and end of treatment (12 weeks). We found that the leves of the important inflammatory markers IL-17A and MDC were significantly reduced in the serum after treatment while the levels of the beneficial adipokine adiponectin was increased.
Featured Image
Why is it important?
This work is important because it shows that by reducing the inflammation in psoriatic skin by effective topical treatment some of the systemic aspects of the disease can be improved. So, not only does the data support the efficacy of this specific treatment, they also suggest that the main driver of the disease is the cutaneous inflammation
Perspectives
Many psoriasis patients in the mild- and moderate segments are dependent on topical treatment for their disease. It has been suggested that these patients may also be at risk for systemic manifestations of the disease in the form of comorbidities eg. cadiovascular disease. The perspective of this work is that you do not necessarily need to treat your disease by systemic treatment (such as biologics) to affect the systemic inflammation etc. The main target organ of psoriasis is the skin and effective treatment of the skin with a topical product you can both reduce cutaneous symptoms and systemic markers of the disease.
Mads Almose Røpke
LEO Pharma A/S
Read the Original
This page is a summary of: Changes in interleukin-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study, British Journal of Dermatology, December 2017, Wiley,
DOI: 10.1111/bjd.15814.
You can read the full text:
Contributors
The following have contributed to this page
